Onchocerca volvulus-specific antibody and cellular responses in onchocerciasis patients treated annually with ivermectin for 30 years and exposed to parasite transmission in central Togo
<h4>Background</h4> Annual mass drug administrations (MDA) of ivermectin will strongly reduce Onchocerca volvulus microfilariae (mf) in the skin and in the onchocerciasis patients’ eyes. Ivermectin treatment will also affect the expression of immunity in patients, such that activated imm...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-05-01
|
| Series: | PLoS Neglected Tropical Diseases |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9064110/?tool=EBI |
| _version_ | 1811338505790423040 |
|---|---|
| author | Saskia I. Johanns Richard G. Gantin Bawoubadi Wangala Kossi Komlan Wemboo A. Halatoko Meba Banla Potchoziou Karabou Adrian JF Luty Hartwig Schulz-Key Carsten Köhler Peter T. Soboslay |
| author_facet | Saskia I. Johanns Richard G. Gantin Bawoubadi Wangala Kossi Komlan Wemboo A. Halatoko Meba Banla Potchoziou Karabou Adrian JF Luty Hartwig Schulz-Key Carsten Köhler Peter T. Soboslay |
| author_sort | Saskia I. Johanns |
| collection | DOAJ |
| description | <h4>Background</h4> Annual mass drug administrations (MDA) of ivermectin will strongly reduce Onchocerca volvulus microfilariae (mf) in the skin and in the onchocerciasis patients’ eyes. Ivermectin treatment will also affect the expression of immunity in patients, such that activated immune defenses may help control and contribute to clearance of mf of O. volvulus. Longitudinal surveys are a prerequisite to determining the impact of ivermectin on the status of anti-parasite immunity, notably in risk zones where parasite transmission and active O. volvulus infections persist. <h4>Methodology/Principal findings</h4> Onchocerciasis patients were treated annually with ivermectin and their Onchocerca volvulus antigen (OvAg) specific IgG and cellular responses were investigated before and at 30 years post initial ivermectin treatment (30yPT). Repeated annual ivermectin treatments eliminated persisting O. volvulus microfilariae (mf) from the skin of patients and abrogated patent infections. The OvAg-specific IgG1 and IgG4 responses were diminished at 30yPT to the levels observed in endemic controls. Prior to starting ivermectin treatment, OvAg-induced cellular productions of IL-10, IFN-γ, CCL13, CCL17 and CCL18 were low in patients, and at 30yPT, cellular cytokine and chemokine responses increased to the levels observed in endemic controls. In contrast, mitogen(PHA)- induced IL-10, IFN-γ, CCL17 and CCL18 cellular production was diminished. This divergent response profile thus revealed increased parasite antigen-specific but reduced polyclonal cellular responsiveness in patients. The transmission of O. volvulus continued at the patients’ location in the Mô river basin in central Togo 2018 and 2019 when 0.58% and 0.45%, respectively, of Simulium damnosum s.l. vector blackflies carried O. volvulus infections. <h4>Conclusions/Significance</h4> Repeated annual ivermectin treatment of onchocerciasis patients durably inhibited their patent O. volvulus infections despite ongoing low-level parasite transmission in the study area. Repeated MDA with ivermectin affects the expression of immunity in patients. O. volvulus parasite-specific antibody levels diminished to levels seen in infection-free endemic controls. With low antibody levels, antibody-dependent cellular cytotoxic responses against tissue-dwelling O. volvulus larvae will weaken. O. volvulus antigen inducible cytokine and chemokine production increased in treated mf-negative patients, while their innate responsiveness to mitogen declined. Such lower innate responsiveness in elderly patients could contribute to reduced adaptive immune responses to parasite infections and vaccines. On the other hand, increased specific cellular chemokine responses in mf-negative onchocerciasis patients could reflect effector cell activation against tissue invasive larval stages of O. volvulus. The annual Simulium damnosum s.l. biting rate observed in the Mô river basin was similar to levels prior to initiation of MDA with ivermectin, and the positive rtPCR results reported here confirm ongoing O. volvulus transmission. Author summary Onchocerciasis is a neglected tropical disease, and a major cause of debilitating skin disease and ocular damage that can lead to irreversible blindness. Annual mass drug administrations (MDA) of ivermectin strongly reduces the load of Onchocerca volvulus microfilaria (mf) in the skin and in the patients’ eyes. Evolution of onchocerciasis as a disease is prevented by MDA, but recent studies have shown that O. volvulus transmission has not been completely interrupted. Repeated MDA with ivermectin affects immune responses, such that activated immune defenses may enhance clearance of mf of O. volvulus. Longitudinal surveys are required to determine the impact of ivermectin on the status of immunity, notably in risk zones where parasite transmission and active O. volvulus infections persist. We examined the changes of O. volvulus parasite-specific antibody and cellular immune responsiveness in patients treated annually with ivermectin for 30 years. Treatment prevented patent O. volvulus infections, whilst parasite antigen-specific cytokine and chemokine responses increased but O.volvulus-specific antibody responses declined. Such decreased antibody levels could weaken antibody-dependent cellular cytotoxic responses to infective and tissue-dwelling O. volvulus larvae. Strengthened monocyte attracting and activation regulated chemokine responses could enhance effector cell migration and activation against larval stages of O.volvulus, possibly also eliciting resistance to further parasite infections. |
| first_indexed | 2024-04-13T18:11:52Z |
| format | Article |
| id | doaj.art-12c9c549706e41ae9a07b066a5bf59d0 |
| institution | Directory Open Access Journal |
| issn | 1935-2727 1935-2735 |
| language | English |
| last_indexed | 2024-04-13T18:11:52Z |
| publishDate | 2022-05-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS Neglected Tropical Diseases |
| spelling | doaj.art-12c9c549706e41ae9a07b066a5bf59d02022-12-22T02:35:51ZengPublic Library of Science (PLoS)PLoS Neglected Tropical Diseases1935-27271935-27352022-05-01165Onchocerca volvulus-specific antibody and cellular responses in onchocerciasis patients treated annually with ivermectin for 30 years and exposed to parasite transmission in central TogoSaskia I. JohannsRichard G. GantinBawoubadi WangalaKossi KomlanWemboo A. HalatokoMeba BanlaPotchoziou KarabouAdrian JF LutyHartwig Schulz-KeyCarsten KöhlerPeter T. Soboslay<h4>Background</h4> Annual mass drug administrations (MDA) of ivermectin will strongly reduce Onchocerca volvulus microfilariae (mf) in the skin and in the onchocerciasis patients’ eyes. Ivermectin treatment will also affect the expression of immunity in patients, such that activated immune defenses may help control and contribute to clearance of mf of O. volvulus. Longitudinal surveys are a prerequisite to determining the impact of ivermectin on the status of anti-parasite immunity, notably in risk zones where parasite transmission and active O. volvulus infections persist. <h4>Methodology/Principal findings</h4> Onchocerciasis patients were treated annually with ivermectin and their Onchocerca volvulus antigen (OvAg) specific IgG and cellular responses were investigated before and at 30 years post initial ivermectin treatment (30yPT). Repeated annual ivermectin treatments eliminated persisting O. volvulus microfilariae (mf) from the skin of patients and abrogated patent infections. The OvAg-specific IgG1 and IgG4 responses were diminished at 30yPT to the levels observed in endemic controls. Prior to starting ivermectin treatment, OvAg-induced cellular productions of IL-10, IFN-γ, CCL13, CCL17 and CCL18 were low in patients, and at 30yPT, cellular cytokine and chemokine responses increased to the levels observed in endemic controls. In contrast, mitogen(PHA)- induced IL-10, IFN-γ, CCL17 and CCL18 cellular production was diminished. This divergent response profile thus revealed increased parasite antigen-specific but reduced polyclonal cellular responsiveness in patients. The transmission of O. volvulus continued at the patients’ location in the Mô river basin in central Togo 2018 and 2019 when 0.58% and 0.45%, respectively, of Simulium damnosum s.l. vector blackflies carried O. volvulus infections. <h4>Conclusions/Significance</h4> Repeated annual ivermectin treatment of onchocerciasis patients durably inhibited their patent O. volvulus infections despite ongoing low-level parasite transmission in the study area. Repeated MDA with ivermectin affects the expression of immunity in patients. O. volvulus parasite-specific antibody levels diminished to levels seen in infection-free endemic controls. With low antibody levels, antibody-dependent cellular cytotoxic responses against tissue-dwelling O. volvulus larvae will weaken. O. volvulus antigen inducible cytokine and chemokine production increased in treated mf-negative patients, while their innate responsiveness to mitogen declined. Such lower innate responsiveness in elderly patients could contribute to reduced adaptive immune responses to parasite infections and vaccines. On the other hand, increased specific cellular chemokine responses in mf-negative onchocerciasis patients could reflect effector cell activation against tissue invasive larval stages of O. volvulus. The annual Simulium damnosum s.l. biting rate observed in the Mô river basin was similar to levels prior to initiation of MDA with ivermectin, and the positive rtPCR results reported here confirm ongoing O. volvulus transmission. Author summary Onchocerciasis is a neglected tropical disease, and a major cause of debilitating skin disease and ocular damage that can lead to irreversible blindness. Annual mass drug administrations (MDA) of ivermectin strongly reduces the load of Onchocerca volvulus microfilaria (mf) in the skin and in the patients’ eyes. Evolution of onchocerciasis as a disease is prevented by MDA, but recent studies have shown that O. volvulus transmission has not been completely interrupted. Repeated MDA with ivermectin affects immune responses, such that activated immune defenses may enhance clearance of mf of O. volvulus. Longitudinal surveys are required to determine the impact of ivermectin on the status of immunity, notably in risk zones where parasite transmission and active O. volvulus infections persist. We examined the changes of O. volvulus parasite-specific antibody and cellular immune responsiveness in patients treated annually with ivermectin for 30 years. Treatment prevented patent O. volvulus infections, whilst parasite antigen-specific cytokine and chemokine responses increased but O.volvulus-specific antibody responses declined. Such decreased antibody levels could weaken antibody-dependent cellular cytotoxic responses to infective and tissue-dwelling O. volvulus larvae. Strengthened monocyte attracting and activation regulated chemokine responses could enhance effector cell migration and activation against larval stages of O.volvulus, possibly also eliciting resistance to further parasite infections.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9064110/?tool=EBI |
| spellingShingle | Saskia I. Johanns Richard G. Gantin Bawoubadi Wangala Kossi Komlan Wemboo A. Halatoko Meba Banla Potchoziou Karabou Adrian JF Luty Hartwig Schulz-Key Carsten Köhler Peter T. Soboslay Onchocerca volvulus-specific antibody and cellular responses in onchocerciasis patients treated annually with ivermectin for 30 years and exposed to parasite transmission in central Togo PLoS Neglected Tropical Diseases |
| title | Onchocerca volvulus-specific antibody and cellular responses in onchocerciasis patients treated annually with ivermectin for 30 years and exposed to parasite transmission in central Togo |
| title_full | Onchocerca volvulus-specific antibody and cellular responses in onchocerciasis patients treated annually with ivermectin for 30 years and exposed to parasite transmission in central Togo |
| title_fullStr | Onchocerca volvulus-specific antibody and cellular responses in onchocerciasis patients treated annually with ivermectin for 30 years and exposed to parasite transmission in central Togo |
| title_full_unstemmed | Onchocerca volvulus-specific antibody and cellular responses in onchocerciasis patients treated annually with ivermectin for 30 years and exposed to parasite transmission in central Togo |
| title_short | Onchocerca volvulus-specific antibody and cellular responses in onchocerciasis patients treated annually with ivermectin for 30 years and exposed to parasite transmission in central Togo |
| title_sort | onchocerca volvulus specific antibody and cellular responses in onchocerciasis patients treated annually with ivermectin for 30 years and exposed to parasite transmission in central togo |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9064110/?tool=EBI |
| work_keys_str_mv | AT saskiaijohanns onchocercavolvulusspecificantibodyandcellularresponsesinonchocerciasispatientstreatedannuallywithivermectinfor30yearsandexposedtoparasitetransmissionincentraltogo AT richardggantin onchocercavolvulusspecificantibodyandcellularresponsesinonchocerciasispatientstreatedannuallywithivermectinfor30yearsandexposedtoparasitetransmissionincentraltogo AT bawoubadiwangala onchocercavolvulusspecificantibodyandcellularresponsesinonchocerciasispatientstreatedannuallywithivermectinfor30yearsandexposedtoparasitetransmissionincentraltogo AT kossikomlan onchocercavolvulusspecificantibodyandcellularresponsesinonchocerciasispatientstreatedannuallywithivermectinfor30yearsandexposedtoparasitetransmissionincentraltogo AT wembooahalatoko onchocercavolvulusspecificantibodyandcellularresponsesinonchocerciasispatientstreatedannuallywithivermectinfor30yearsandexposedtoparasitetransmissionincentraltogo AT mebabanla onchocercavolvulusspecificantibodyandcellularresponsesinonchocerciasispatientstreatedannuallywithivermectinfor30yearsandexposedtoparasitetransmissionincentraltogo AT potchozioukarabou onchocercavolvulusspecificantibodyandcellularresponsesinonchocerciasispatientstreatedannuallywithivermectinfor30yearsandexposedtoparasitetransmissionincentraltogo AT adrianjfluty onchocercavolvulusspecificantibodyandcellularresponsesinonchocerciasispatientstreatedannuallywithivermectinfor30yearsandexposedtoparasitetransmissionincentraltogo AT hartwigschulzkey onchocercavolvulusspecificantibodyandcellularresponsesinonchocerciasispatientstreatedannuallywithivermectinfor30yearsandexposedtoparasitetransmissionincentraltogo AT carstenkohler onchocercavolvulusspecificantibodyandcellularresponsesinonchocerciasispatientstreatedannuallywithivermectinfor30yearsandexposedtoparasitetransmissionincentraltogo AT petertsoboslay onchocercavolvulusspecificantibodyandcellularresponsesinonchocerciasispatientstreatedannuallywithivermectinfor30yearsandexposedtoparasitetransmissionincentraltogo |